Steven Cohen’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-568,151
| Closed | -$57.9M | – | 2992 |
|
|
2023
Q2 | $57.9M | Buy |
568,151
+204,051
| +56% | +$19.3M | 0.17% | 152 |
|
|
2023
Q1 | $33.1M | Buy |
+364,100
| New | +$21.4M | 0.1% | 246 |
|
|
2022
Q4 | – | Sell |
-1,810,647
| Closed | -$45.5M | – | 1873 |
|
|
2022
Q3 | $45.5M | Buy |
+1,810,647
| New | +$50.2M | 0.18% | 153 |
|
|
2021
Q2 | – | Sell |
-58,800
| Closed | -$5.86M | – | 1225 |
|
|
2021
Q1 | $5.86M | Buy |
58,800
+17,800
| +43% | +$2.08M | 0.03% | 541 |
|
|
2020
Q4 | $5.07M | Buy |
+41,000
| New | +$5.39M | 0.02% | 582 |
|
|
2020
Q3 | – | Sell |
-146,938
| Closed | -$22.9M | – | 1144 |
|
|
2020
Q2 | $22.9M | Sell |
146,938
-29,360
| -17% | -$4.46M | 0.15% | 188 |
|
|
2020
Q1 | $25.4M | Sell |
176,298
-52,002
| -23% | -$10M | 0.21% | 142 |
|
|
2019
Q4 | $46.7M | Sell |
228,300
-131,788
| -37% | -$24M | 0.25% | 115 |
|
|
2019
Q3 | $28.9M | Buy |
360,088
+42,788
| +13% | +$3.63M | 0.18% | 165 |
|
|
2019
Q2 | $29.9M | Buy |
317,300
+26,700
| +9% | +$2.31M | 0.16% | 166 |
|
|
2019
Q1 | $24.8M | Sell |
290,600
-10,600
| -4% | -$880K | 0.11% | 209 |
|
|
2018
Q4 | $16.9M | Sell |
301,200
-448,600
| -60% | -$27.4M | 0.08% | 293 |
|
|
2018
Q3 | $61.3M | Buy |
749,800
+550,706
| +277% | +$38.8M | 0.25% | 105 |
|
|
2018
Q2 | $6.96M | Buy |
+199,094
| New | +$6.06M | 0.03% | 531 |
|
Other funds holding RETA
Steven Cohen's RETA Position: Q3 2023 in Review
Steven Cohen sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 568,151 shares — an estimated $57.9M sold.
Steven Cohen first reported a position in RETA in Q2 2018 and held it in 14 quarters. The position peaked at $61.3M in Q3 2018. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.
- Steven Cohen reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
- Steven Cohen sold 568,151 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $57.9M.
- Steven Cohen first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2018 and held it in 14 quarters.
- Steven Cohen's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $61.3M in Q3 2018.
- 2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.
Based on Point72 Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.